Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

2002277 citationsJournal Article

Authors

Roy S. Herbst · The University of Texas MD Anderson Cancer Center

Kenneth R. Hess · The University of Texas MD Anderson Cancer Center

Hai T. Tran · The University of Texas MD Anderson Cancer Center

Jennifer Tseng · The University of Texas MD Anderson Cancer Center

Nizar A. Mullani · The University of Texas MD Anderson Cancer Center

Chusilp Charnsangavej · The University of Texas MD Anderson Cancer Center

Abstract

rh-Endo was safe and well tolerated. rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with activity in preclinical models. Evidence of minor antitumor activity was observed and further studies are indicated.

Topics & Keywords

Angiogenesis and VEGF in Cancer Cancer, Hypoxia, and Metabolism Cancer Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 18, pp. 3792-3803

DOI: 10.1200/jco.2002.11.061

Field-Weighted Citation Impact: 11.57